Recognizing that resilient cancer cells (also referred to as metastatic dormant cells) may require the use of drugs that target cell cycle control, it would be convenient to add an activity related to cell cycle control to the design of hunter-killer peptides, as in the case of IP-1. The gene discussed is IKBKG; the disease is cancer.